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Abstract
Serological analysis of cDNA expression library (SEREX) was employed to identify cancer-associated genes. By screening cDNA
expression libraries with sera of patients with lung cancers, we identified a total of 49 genes that specifically reacted with the sera of patients
with lung cancers. Among these, we characterized a novel gene with expression pattern similar to that of cancer/testis antigens. Its open
reading frame is 1920 bp in size and encodes for putative protein composed of 639 amino acids. Southern blot analysis reveals that this gene
exists as single copy. In vitro transcription/translation and Western blot analysis confirm that this gene encodes a protein of 73 kDa in size.
The comparison of cDNA and genomic sequences reveals that it is composed of 11 exons and 10 introns. This gene displays testis-specific
expression among normal tissues, and wide expression among various cancer tissues and cancer cell lines. A study using GFP fusion
construct reveals mainly nuclear localization of CAGE-1 protein. The expression of this clone is relatively higher in cancer tissues compared
with their surrounding non-cancerous tissues. This suggests that overexpression of CAGE-1 may be associated with the progression of tumor.
Because of its association with cancer, this gene was named cancer-associated gene-1 (CAGE-1). Given the fact that several cancer/testis
antigens reportedly induce cytolytic T lymphocyte (CTL) reactions, it is reasonable that this gene will be a valuable target for cancer
immunotherapy. The exact functional role of CAGE-1 in tumorigenesis remains to be seen.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The successful treatment of cancer patients requires the
recognition by the immune system of tumor-specific anti-
gens.
The definition of antigens that are expressed in tumor
cells and elicit immune responses in the autologous host is
a major aim of tumor immunology [1]. There has been a
major progress in the identification and characterization of
tumor-associated antigens over the past decade. Over the
past decade, SEREX has been extensively used to identify
tumor antigens. The number of tumor antigens identified by
SEREX is increasing rapidly. SEREX has been used to
identify antigens associated with various malignancies
including leukemia [2], esophageal squamous cell carci-
noma [3], lung cancer [4], colon cancer [5], gastric cancer
[6], and renal cancer [7]. These SEREX-positive antigens
are classified into several categories. Genes such as
MAGE, BAGE, and LAGE are all expressed in various
tumors but not in normal tissues except for testis and
placenta [8–13]. These genes are so-called cancer/testis
antigens. These cancer/testis antigens are recognized by
cytolytic T lymphocytes (CTL). The antigens encoded by
genes that are expressed only in tumors and in germ-line
cells appear to be tumor-specific because the spermatogenic
cells do not express HLA molecules. Differentiation anti-
gens, including tyrosinase [14] and gp100 [15], are those
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that are expressed in normal melanocytes and melanoma.
There are some mutated genes including p16 and beta-
catenin gene [16,17] whose gene products are recognized
by sera of patients but not by normal individuals. In this
study, we carried out SEREX to identify cancer-associated
genes. By screening cDNA expression libraries with sera of
patients with lung cancer, we identified genes that were
reactive with sera of patients with lung cancer. Among
these, we were interested in a novel gene that showed
expression pattern typical of cancer/testis antigens. Here we
report the identification and characterization of a novel
cancer/testis antigen.
2. Materials and methods
2.1. Materials
Primary tumor tissues used in RT-PCRwere obtained with
informed consent from cancer patients who underwent sur-
gery at Seoul National University Hospital (Seoul, Korea).
Tumor tissues and their surrounding tissues were obtained
from patients who underwent surgical resection at Seoul
National University Hospital. Anti-human IgG Ab conju-
gated with alkaline phosphatase was obtained from KPL
Company (Gaithersburg, MD). All primers were commer-
cially synthesized by the Bioneer Company (Chungwon,
Korea). Cancer cell lines used in this study were obtained
from Korea Cell Line Bank (Seoul, Korea). NBT and BCIP
were obtained from Sigma Chemical Company (St. Louis,
MO).
2.2. Construction of cDNA expression libraries
A total of 5 Ag of human testicular poly(A)+ (Clontech
Company, Palo Alto, CA) RNA or 5 Ag of poly(A)+ RNA of
each human lung cancer cell line was used for the construc-
tion of cDNA expression library. Construction of cDNA
expression library was carried out according to the instruc-
tion manual provided by the manufacturer (Stratagene, La
Jolla, CA).
Each library consisted of 2 106 primary recombinants
on average and 5 105 of them were used for immuno-
screening.
2.3. Immunoscreening of the cDNA expression library
Each cDNA expression library was screened with pooled
sera of five lung cancer patients. Screening procedure was
done according to the instruction manual provided by the
manufacturer (Stratagene). Before carrying out screening,
each serum was absorbed. This is because of the fact that
human sera contain antibodies against bacterial proteins to
cause serious background problems. For absorption, E. coli/
phage lysates (1:10 diluted in wash buffer) was incubated
with nitrocellulose membrane for 30 min. After incubation,
membrane was washed with wash buffer (KPL). Mean-
while, pooled sera of patients were diluted in wash buffer.
To this, membrane incubated with E. coli/phage lysates was
added. Incubation continued for 1 h. For screening of
cDNA expression library, plate containing 10,000–20,000
plaques was covered with IPTG (10 mM)-treated nitro-
cellulose membrane. Incubation continued for 8–12 h at 37
jC. Membrane was washed with wash buffer. After wash-
ing, membrane was incubated with blocking solution [5%
(w/v) BSA] and incubation continued for 1 h. After incu-
bation, membrane was incubated with preadsorbed sera for
2 h.
After washing, membrane was incubated with secondary
antibody (anti-human IgG Ab) for 1 h. After washing,
Table 1
Genes isolated by SEREX of the lung cancer cell lines or human testis
tissue
Designation Number of
clones
GenBank
number
Gene SEREX DB
T-1 4 AJ303380 serine/threonine
kinase 33
no
T-2 3 AB035747 carbonic
anhydrase II
no
T-3 2 AF334812 Rab11
interacting
protein
no
T-4 1 BC000684 PDGF
associated
protein
no
T-5 1 BC007065 GST theta 1 yes
T-6 1 U28964 14-3-3 protein no
T-7 1 AF414185 CAGE-1
(in this study)
no
Lu-1 55 XM_
008691
RalA binding
protein
yes
Lu-2 22 BC001047 Homo sapiens,
nucleolar
autoantigen
(55 kDa)
no
Lu-3 19 XM_
006446
ZW10 homolog,
centromere/
kinetocore protein
yes
Lu-4 12 AF129085 Carboxy terminus of
Hsp70-interacting
protein (CHIP)
yes
Lu-5 11 XM_
001790
SHC
transforming
protein 1
no
Lu-6 6 X98260 M-phase
phosphoprotein,
mpp11
yes
Lu-7 3 NM_
003646
Diacylglycerol
kinase zeta
no
Lu-8 1 NM_
005836
Translational
inhibitor protein
p14.5 (UK114)
no
142
T represents clone identified by screening of human testis cDNA expression
library. Lu represents clone identified by screening of cDNA expression
library of lung cancer cell line.
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Fig. 1. Expression analysis of CAGE-1 gene. RT-PCR of CAGE-1 gene in normal tissues (A), cancer cells (B), and cancer tissues (C). RT-PCR without reverse
transcriptase served as negative control. Broken arrows denote primer dimers.
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detection of immunoreactive clones was done by color
reaction using NBT (0.3 mg/ml)/BCIP (0.15 mg/ml) devel-
oping solution.
2.4. Sequencing of immunoreactive clones
Immunoreactive clone was excised in vivo to plasmid
form. Plasmid DNAwas purified by commercial kit (Qiagen
Company, Westburg, Leusden, the Netherlands). Sequences
were obtained from phage clones. Sequencing was done by
ABI PRISM 310 Genetic Analyzer Automated Sequencer
(Perkin Elmer, Foster City, CA).
2.5. RT-PCR
Analysis of expression pattern of the immunoreactive
clone was carried out according to the standard procedures.
Briefly, total RNA was isolated from various cancer tissues
or cell lines by using an RNAqueous solution kit (Ambion,
Austin, TX). Messenger RNA was isolated by using an
oligodT cellulose. Subsequently obtained mRNA was con-
verted into cDNA by superscript reverse transcriptase (Life
Technologies Inc., Gaithersburg, MD).
Primer sequences 5V-AGGAAGGCGTGTTGAGTA-
GCC-3V(forward, CAGE-1) and 5V-GAACTCCGCAGAGA-
CAGGTG-3V(reverse, CAGE-1) were used for all RT-PCR
in this study. All primers were commercially synthesized
(Bioneer). RT-PCR was performed for 32 cycles in a Gene
Amp PCR system (Perkin-Elmer) at 94 jC for 30 s, 60 jC
for 30 s, and 72 jC for 1 min. The reaction yielded a 230-
bp PCR product. Amplification of GAPDH was performed
for 30 cycles at 94 jC for 30 s, 60 jC for 30 s, and 72 jC
for 1 min.
2.6. Seroreactivity
For determination of seroreactivity of each immunoreac-
tive clone, e¨-ZAP phage without insert was mixed with test
clone and served as negative control. Control and test clones
were coplated and determination of seroreactivity was done
as in Section 2.1.
2.7. Southern blot hybridization
Ten micrograms of genomic DNA was digested with
BamHI, EcoRI, and HindIII; 0.8-kb insert of CAGE-1
cDNA was used as probe. Southern blot hybridization was
carried out according to the standard procedures [18].
2.8. In vitro transcription/translation of CAGE-1
In vitro transcription/translation of CAGE-1 was carried
out according to the instruction manual provided by the
manufacturer (Promega). Briefly, 1 Ag of pET21a–CAGE-1
construct was mixed with T7 Quick Master Mix (Promega),
1 mM methionine, and incubated at 30 jC for 90 min. After
reaction, reaction product was analyzed on 10% SDS-
PAGE.
2.9. Western blot analysis
E. coli strain BL21, transfected with vector or pGEX4T-
2–CAGE-1 construct, was treated with or without 0.5 mM
IPTG. Cells were lysed in lysis buffer (100 mM NaH2PO4,
10 mM Tris–HCl, 8 M urea). Cell lysates were diluted
with sample buffer and boiled for 5 min. A total of 10 Ag
of cell lysates was run on 10% SDS-PAGE. After electro-
phoresis, proteins were transferred onto PVDF membrane
at 4 jC for 2 h at 100 mA. PVDF membrane was
incubated with blocking buffer for 1 h. After blocking,
membrane was incubated with monoclonal anti-GST
mouse Ab (1: 20 dilution) for 1 h. Membrane was washed
with buffer [1 PBS, 0.1% Tween 20 (v/v)] for a total of
30 min. After washing, membrane was incubated with
HRP-conjugated anti-mouse Ab (1:3,000 dilution) for 1
h. After washing, detection of protein of interest was
carried out by using ECL kit according to the manufactur-
er’s protocol (Amersham International, England). For
detection of GFP–CAGE-1 expression, Western blot anal-
ysis using monoclonal anti-GFP Ab (1:500 dilution) was
carried out. For construction of deleted forms of CAGE-1
protein, cloning of PCR products (deleted forms of CAGE-
1 gene) into pGEX4T-2–CAGE-1 was carried out. Sub-
sequently obtained constructs were transfected into E. coli
strain BL21.
2.10. GFP–CAGE-1 construct and transfection
To construct GFP–CAGE-1 fusion gene, RT-PCR prod-
uct of CAGE-1 (1.9 kb) was subcloned into pEGFP-C1
vector (Clonetech). Briefly, the PCR product was cut with
XhoI and cloned into XhoI site of pEGFP-C1 vector. Four
Table 2
Summary of expression of CAGE-1
Expression
Normal tissues Cancer tissues and cell lines
Temporal lobe 0/2 Gastric cancer tissue 15/22
Parietal lobe 0/2 Cervical cancer tissue 19/20
Spinal cord 0/1 Lung cancer tissue 6/6
Liver 0/2 Prostate cancer cell line 0/1
Kidney 0/2 Sarcoma cell line 1/1
Spleen 0/3 Myeloma cell line 2/4
Stomach 0/3 Leukemia cell line 0/12
Lung 0/2 Pancreatic cancer cell line 1/2
Small intestine 0/2 Gastric cancer cell line 9/10
Large intestine 0/2 Lung cancer cell line 7/7
Muscle 0/2 Hepatic cancer cell line 9/10
Trachea 0/1 Cervical cancer cell line 7/7
Skin 0/1 Melanoma cell line 5/5
Ovary 0/2 Breast cancer cell line 3/4
Thymus 0/1 Kidney cancer cell line 3/4
Testis 2/2 Colon cancer cell line 2/3
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micrograms of GFP–CAGE-1 construct, under the control
of CMV promoter, was transiently transfected into human
cervical cancer cell line C33A by lipofectin method. Trans-
fection was carried out according to the instruction manual
provided by the manufacturer (Gibco BRL). Transient
expression of the fusion protein was checked within 48 h.
To visualize expression of the fusion protein, cells were
fixed with 3.7% (v/v) formaldehyde. DAPI (4V, 6-diamidino-
2-phenylindole, Calbiochem), 1:5000, was used for staining
of cell nuclei.
3. Results and discussion
3.1. Selection of immunoreactive clones by SEREX
We were interested in identifying genes that are associ-
ated with lung cancer. We employed SEREX to this end.
Since its discovery in early 1990s, SEREX has been used to
identify genes associated with various cancers. We also
wanted to identify cancer/testis antigens that might be used
as targets of cancer immunotherapy. cDNA expression
Fig. 2. Structural features of CAGE-1. (A) Nucleotide and amino acid sequences of CAGE-1. Primers (CAGE-1F and CAGE-1R) for RT-PCR are shown. Start
and stop codons are shaded. Poly(A) signal sequences are underlined. (B) Alignment of human CAGE-1 and monkey homologs (AB070119, AB070045).
Identical residues are highlighted as white text on a black background. (.) N-glycosylation signal sequences; (+) PKC-dependent phosphorylation sites; (*)
casein kinase-dependent phosphorylation sites. (C) Genomic structure of CAGE-1. For this, cDNA and genomic sequences of CAGE-1 were compared. The
boxes indicate exons. Thick lines indicate introns. (D) Southern blot hybridized with 0.8-kb insert of CAGE-1 cDNA. Each lane was loaded with 10 Ag of
genomic DNA from the AGS cell line digested with the indicated restriction enzymes.
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libraries from three lung cancer cell lines (adenosquamous
type) and human testis tissue were constructed. By screen-
ing these cDNA expression libraries with the pooled sera
(1:200 dilution) of five patients with lung cancers, a total of
49 independent clones that react specifically with sera of
patients with lung cancers were identified. All these immu-
noreactive clones were excised in vivo and their sequences
were determined. Thirty-two clones identified in this screen
have not been reported in SEREX DB (http://www.licr.org).
Table 1 shows a partial list of genes isolated by SEREX; 55,
22, 19, and 11 overlapping clones respectively represents ral
A binding protein, nucleolar autoantigen, ZW10 homolog,
and SHC transforming protein 1. We searched SEREX
database to check whether genes identified in this screen
Fig. 2 (continued).
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were previously reported. Genes including M-phase protein
11, hsp70, GST theta, and ZW10 were previously reported
in SEREX database. These genes are known to be associated
with various cancers including breast, hepatic, ovarian, and
stomach cancer. However, these genes have not been known
to be associated with lung cancer. Among those 49 genes
identified in this study, 32 of them are known and the other 17
genes are functionally uncharacterized. We searched EST
database to check the expression pattern of each gene. Almost
all of the genes displayed ubiquitous expression pattern.
According to allogenic test, all these clones showed reactivity
to the sera of patients with lung cancers. However, none of
these clones reacted with sera of 19 healthy individuals (data
not shown). The sensitivities of these clones range 4.7–25%
(data not shown).
3.2. Expression analysis of novel clone
After searching EST database, we found that the expres-
sion pattern of one clone has never been determined. Since
it was identified by screening of testis cDNA expression
library with sera of patients with lung cancers, we checked
the possibility of this clone being cancer/testis antigen. First,
we determined the expression pattern of this clone. For this,
we carried out RT-PCR using a panel of normal tissues. We
designed primers based on the partial sequences of this
clone. This clone showed testis-specific expression among
normal tissues (Fig. 1A). The expression of this clone in
other normal tissues was negligible. Because this clone had
expression pattern similar to that of the MAGE, BAGE, and
GAGE, we thought that this clone might be another cancer/
Fig. 2 (continued).
Table 3
Exon– intron structures of the CAGE-1 gene
Exon length Intron phase Splice sites
Exon 1 508 – GT/AG
Exon 2 88 – GT/AG
Exon 3 404 0 GA/AG
Exon 4 1059 0 GT/AG
Exon 5 147 0 GT/AG
Exon 6 111 0 GT/AG
Exon 7 108 0 GT/AG
Exon 8 71 II GT/AG
Exon 9 69 II GT/AG
Exon 10 40 0 GT/AG
Exon 11 238 – GT/AG
Intron phases are indicated by roman numbers. The intron phases refer to
the location of the intron within the codon; 0 indicates that the intron occurs
between codons and II indicates that the intron occurs after the second
nucleotide.
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testis antigen. To check this possibility, we carried out RT-
PCR of various cancer tissues and cancer cell lines. It
showed wide expression in cancer cell lines (Fig. 1B) and
cancer tissues (Fig. 1C). Table 2 shows a summary of
expression of this clone. It showed wide expression in other
various cancer cell lines including cervical, melanoma,
hepatic, renal, myeloma, and breast. However, expression
was not shown in leukemia cell line (0/12). Taken together,
these data suggest that this clone indeed is a new member of
cancer/testis antigens.
3.3. Structural features and expression analysis of novel
clone (CAGE-1)
By in vivo excision, we found that this clone had 3-kb
insert. We carried out full sequencing. The longest open
Fig. 3. Expression and localization of CAGE-1 protein. (A) E. coli cells (BL21 strain) transfected with GST or various forms of GST-CAGE-1 were
treated without or with 0.5 mM IPTG for various time intervals and Western blot analysis using monoclonal anti-GST antibody was carried out. * denotes
protein band encoded by each of deleted form of CAGE-1 protein. For induction of deleted forms of CAGE-1, cells were treated with 0.5 mM of IPTG
for 6 h. (B) In vitro transcription/translation was carried out according to the instruction manual provided by the manufacturer (Promega). (C)
Localization of CAGE-1 protein in C33A cervical cancer cell line. GFP (a, c) or GFP-CAGE-1 (b, d) under the control of CMV promoter was transfected
into cervical cancer cell line C33A. Localization of GFP (a) or GFP-CAGE-1 (b) was shown. DAPI images show cell nuclei (c, d). (D) Human cervical
cancer cell line C33A was transiently transfected with GFP-CAGE-1 construct or GFP vector. Western blot analysis using monoclonal anti-GFP Ab was
carried out.
S. Park et al. / Biochimica et Biophysica Acta 1625 (2003) 173–182180
reading frame is 1920 bp in size and it encodes for putative
protein composed of 639 amino acids (Fig. 2A). By search-
ing GenBank database, we found monkey homologs of
CAGE-1. At the amino acid level, it shows 76% and 71%
identity with that of Macaca fascicularis homologs (cDNA
clone QtSA–14351 and QtsA–12423) (Fig. 2B). These
monkey homologs are known to display testis-specific
expression. Hydropathicity profile analysis revealed that
this clone encodes for soluble protein. This clone contains
two consensus glycosylation sites suggesting that this might
encode for a glycoprotein. There are 10 consensus protein
kinase C phosphorylation sites in this clone. This suggests
that this clone might be involved in signaling pathway. This
clone was found to consist of 11 exons and 10 introns (Fig.
2C) by comparing cDNA and genomic sequences reported
in GenBank database. All exon/intron boundaries comply
with GT/AG rule except intron 3, which shows GA/AG.
The first methionine codon is located at exon 3, and as is the
case with most mammalian mRNAs, the start codon is
surrounded by a purine in position  3 and a G in position
+ 4. Table 3 shows exon–intron structures of the CAGE-1.
All exons end with an intron phase of 0 except exons 8 and
9, which have intron phases II. By checking GenBank
database, this clone was found to be located at chromosome
6p24.1–p25.3. Many of those cancer/testis antigens are
known to be located on chromosome X. However, cancer/
testis antigen gene HAGE is located on chromosome 6q12–
q13. Southern blot hybridization showed that genomic DNA
digested with various enzymes yielded single fragment,
suggesting that CAGE-1 exists as single copy unlike other
cancer/testis antigens (Fig. 2D). To determine molecular
weight of the protein, Western blot analysis was performed
on lysates prepared from E. coli BL21 strain by using
monoclonal anti GST antibody. GST–CAGE-1 fusion con-
struct showed 100-kDa band, suggesting that CAGE-1
encoded a protein of 73 kDa in size. (Fig. 3A). We also
transfected GFP–CAGE-1 fusion construct into human
cervical carcinoma cell line and carried out Western blot
analysis using monoclonal anti-GFP Ab. We found that
CAGE-1 encoded a protein of 73 kDa in size (data not
shown).
We carried out in vitro transcription/translation reaction
and found that CAGE-1 encoded a protein of 73 kDa in size
(Fig. 3B). To determine localization of the CAGE protein,
GFP–CAGE-1 expression vector was transiently trans-
fected into cervical cancer cell line C33A. CAGE-1 protein
showed mainly nuclear localization (Fig. 3C (b)). Immuno-
fluorescence staining with monoclonal antibody against
CAGE-1 protein would clearly reveal cellular localization
of CAGE-1 protein.
3.4. CAGE-1 is overexpressed in tumor tissues compared
with surrounding tissues
We checked whether CAGE-1 is overexpressed in cancer
tissues compared with their surrounding non-cancerous
tissues. For this, cancer tissues and their surrounding non-
cancerous tissues were obtained from patients with gastric
cancers who underwent surgical resection. We compared
expression level of CAGE-1 between gastric cancer tissues
and surrounding gastric mucosa tissues. Although these
gastric mucosa tissues are not normal in that some of them
express CAGE-1, we found that 46% (7/15) of the tumor
tissues overexpressed CAGE-1 compared with surrounding
gastric mucosa tissues (Fig. 4). These data suggest that
CAGE-1 might be associated with progression of tumori-
genesis. We did not find correlation between the over-
expression of CAGE-1 and clinical phenotypes of these
gastric cancer tissues.
4. Discussion
In this study, we carried out SEREX analysis to identify
genes that react with sera of patients with lung cancer, but
not with those of healthy individuals. We identified a total of
49 genes that specifically reacted with sera of patients with
lung cancer. Most of these genes are highly homologous to
known genes (Table 1). Searching for Database revealed
that most of these genes were ubiquitously expressed genes.
We identified a novel gene, CAGE-1, whose expression
pattern has never been determined. CAGE-1 gene showed
testis-specific expression among normal tissues and dis-
played wide expression in a variety of cancer cell lines
and cancer tissues (Fig. 1, Table 2). Based on its expression,
it is reasonable that CAGE-1 be a new member of cancer/
testis antigen gene. We cloned and sequenced CAGE-1
gene. Its open reading frame is 1920 bp in size and encodes
for protein composed of 639 amino acids (Fig. 2A). Two
monkey homologs of CAGE-1 have been identified (Fig.
2B). CAGE-1 protein shows 76% and 71% sequence
homology with these two monkey homologs. Its genomic
structure consists of 11 exons and 10 introns (Fig. 2C, Table
3). Unlike many of those cancer/testis antigens, CAGE-1
gene is localized into chromosome 6 based on Database
search. Some of those cancer/testis genes, including MAGE
Fig. 4. Comparison of expression of CAGE-1 between cancer tissues and surrounding non-cancerous tissues. G denotes gastric cancer tissues; N denotes
surrounding non-cancerous tissues.
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genes, exist as families. However, CAGE-1 gene exists as
single copy (Fig. 2D). In vitro transcription/translation and
Western blot analysis showed that it encoded a protein of 73
kDa in size (Fig. 3A and B). Localization study using GFP–
CAGE-1 showed nuclear localization of CAGE-1 (Fig. 3C).
The fact that CAGE-1 genes show overexpression in cancer
tissues compared with surrounding mucosa tissues suggests
that CAGE-1 may be involved in the progression of tumori-
genesis (Fig. 4).
Given the fact that testis is an immune-privileged site,
this clone might be a cancer-associated antigen. Recently,
there have been reports that several cancer/testis antigens
elicit CTL reactions [19–23] suggesting that cancer/testis
antigens could be developed as immunotherapeutics. In light
of this view, CAGE-1 would be a valuable target of cancer
immunotherapy.
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